Menu

Home

Technology

For Pharma

For Oncologists

Colorectal Cancer

Pancreatic Cancer

About

Contact

Encapsulate

Welcome to the future of personalized oncology

In a 2020-2023 project with the International Space Station National Laboratory (ISSNL), in partnership with Space Tango, we developed the first fully automated tumor-on-a-chip system that can encapsulate, maintain, grow, treat, monitor, and fix patient-derived microtumors in-orbit and onboard the ISSNL (Project #: GA2019-7750). We have developed biomimetic tumor microenvironments that recapitulate the environment of tumors in the human body and that can accurately predict the response of a patient’s cancer cells to chemotherapy drugs. As a result of this working collaboration, we evaluated, developed, and optimized our biochips to ensure compatibility with on-orbit operations. We have demonstrated the capability of our biochips to be fully integrated with the Space Tango’s PAUL system, and with our co-developed automated device, to grow, maintain, and monitor patient-derived microtumors in microgravity.

 

Encapsulate Clinical Studies with 100% Accuracy in Treatment Prediction

Funded by NSF SBIR, Encapsulate has completed its second round of clinical studies in partnership with Hartford Healthcare and Accio Biobank.

Additionally, our biobank can help you identify new therapeutic targets and potential drug resistance mechanisms while also aiding in the development of new diagnostic tools and assays for early cancer detection and patient stratification.
Encapsulate's patient-derived spheroid microtumor-on-a-chip (TOC) technology offers preclinical R&D companies an innovative approach to testing the efficacy of their experimental cancer drugs.  The platform enables the assessment of tumor behavior in a three-dimensional (3D) microenvironment that mimics the in vivo tumor microenvironment. This allows for a more accurate representation of the tumor's response to drugs and treatments and can help identify potential biomarkers and personalized treatment strategies.
Our platform can be used to screen large numbers of drugs and drug combinations, accelerating the drug discovery process and reducing the cost of drug development. Additionally, our platform can help identify new therapeutic targets and potential drug resistance mechanisms.
Testing your experimental chemotherapy drugs on Encapsulate's patient-derived spheroid-based TOC platform provides an innovative and personalized approach to improve the efficiency and success of your drug development program. Our platform offers preclinical R&D companies the opportunity to test their drugs more accurately and efficiently, ultimately leading to better patient outcomes. 

Connect with us.

We can bring you precision.

and save time and money for your project.

Why You should Choose Us

N

Our biobank of patient-derived tumor biopsies offers a diverse range of samples with known genomic and clinical data to enhance the accuracy of your preclinical models. Using our biobank, you can validate your experimental therapeutics, identify potential biomarkers and personalized treatment strategies, and screen many drugs and drug combinations to accelerate the drug discovery process and reduce costs.

N

Additionally, our biobank can help you identify new therapeutic targets and potential drug resistance mechanisms while also aiding in the development of new diagnostic tools and assays for early cancer detection and patient stratification. 

N

 Gain access to a valuable resource that can improve the efficiency and success of your drug development programs. Contact us today to learn more about our patient-derived tumor biobank.

Contact us

Call Us

(two six seven) 290-7779

Email Us

info@encapsulate.bio

Our Location

400 Farmington Ave., Unit 1841

Farmington, CT 06032

Get in touch